Accra, Feb. 01, GNA – The Food and Drugs Authority (FDA) has approved the first herbal medicine for clinical trial on COVID-19 treatment.
It is named Cryptolepis Sanguinolenta, locally known as Nibima.
This was disclosed in a statement issued in Accra on Monday and signed by Mrs Delese A.A. Darko, the Chief Executive Officer of the FDA.
« The Food and Drugs Authority and the National Regulatory Agency in Ghana have approved a herbal medicine; Cryptolepis Sanguinolenta, locally known as Nibima, for clinical trials in January 2021, » it said.
The statement said in search of COVID-19 treatment, researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology submitted a clinical application.
It said the application was to assess the safety and efficacy of Cryptolepois Sanguinolenta as a potential treatment of COVID-19.
This follows results from lab studies conducted by the KNUST Research team, which points in the direction of possible clinical benefits, the statement said.
